Glioma Groups Based on 1p/19q,IDH, andTERTPromoter Mutations in Tumors
Authors:
- Jeanette E. Eckel-PassowJEJeanette E. Eckel-Passow
- Daniel H. LachanceDLDaniel H. Lachance
- Annette M. MolinaroAMAnnette M. Molinaro
- Kyle M. WalshKWKyle M. Walsh
- Paul A. DeckerPDPaul A. Decker
- Hugues SicotteHSHugues Sicotte
- Melike PekmezciMPMelike Pekmezci
- Terri RiceTRTerri Rice
- Matt L. KoselMKMatt L. Kosel
- Ivan V. SmirnovISIvan V. Smirnov
- Gobinda SarkarGSGobinda Sarkar
- Alissa A. CaronACAlissa A. Caron
Top Cited Papers
- 25 June 2015
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 372 (26) , 2499-2508
Abstract
The prediction of clinical behavior, response to therapy, and outcome of infiltrative glioma is challenging. On the basis of previous studies of tumor biology, we defined five glioma molecular groups with the use of three alterations: mutations in the TERT promoter, mutations in IDH, and codeletion of chromosome arms 1p and 19q (1p/19q codeletion). We tested the hypothesis that within groups based on these features, tumors would have similar clinical variables, acquired somatic alterations, and germline variants. We scored tumors as negative or positive for each of these markers in 1087 gliomas and compared acquired alterations and patient characteristics among the five primary molecular groups. Using 11,590 controls, we assessed associations between these groups and known glioma germline variants. Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations. The mean age at diagnosis was lowest (37 years) among patients who had gliomas with only IDH mutations and was highest (59 years) among patients who had gliomas with only TERT mutations. The molecular groups were independently associated with overall survival among patients with grade II or III gliomas but not among patients with grade IV gliomas. The molecular groups were associated with specific germline variants. Gliomas were classified into five principal groups on the basis of three tumor markers. The groups had different ages at onset, overall survival, and associations with germline variants, which implies that they are characterized by distinct mechanisms of pathogenesis. (Funded by the National Institutes of Health and others.)Keywords
This publication has 30 references indexed in Scilit:
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade GliomasNew England Journal of Medicine, 2015
- Telomerase promoter mutations in cancer: an emerging molecular biomarker?Virchows Archiv, 2014
- TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewalProceedings of the National Academy of Sciences, 2013
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951Journal of Clinical Oncology, 2013
- Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402Journal of Clinical Oncology, 2013
- Isocitrate dehydrogenase mutations in gliomasCurrent Opinion in Neurology, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibilityNature Genetics, 2009
- A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with OligodendrogliomaCancer Research, 2006
- Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesisCancer Cell, 2006